IMPEL PHARMACEUTICALS INC: Nasdaq/NYSE listing notice — Impel Pharmaceuticals receives Nasdaq delisting notifications for failing market value requirements

IMPEL PHARMACEUTICALS INC

On April 11, 2023, Impel received Nasdaq notices for non-compliance with MVPHS ($15M minimum) and MVLS ($50M minimum) rules.
Company has 180 calendar days (until October 9, 2023) to regain compliance by closing above thresholds for 10 consecutive business days.
If unable to comply, Impel may request a hearing to appeal a potential delisting determination.
Management will monitor market values and consider options to regain compliance, but no assurance of success.
Common stock trades on Nasdaq under ticker IMPL; failure to comply could lead to delisting.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

IMPEL PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5450(b)(2)(C)

Exact text from the filing

April 11, 2023, Impel Pharmaceuticals Inc. (the “Company”) received two written notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The first notification indicated that as of April 11, 2023, the Company did not meet the $15,000,000 minimum market value of publicly held shares required to maintain continued listing as set forth in Nasdaq Marketplace Rule 5450(b)(2)(C) (the “MVPHS Rule”) for the 30-business day period ended April 5, 2023. The second notification indicated that as of April 11, 2023, the Company did not meet the $50,000,000 minimum

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

IMPEL PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(C)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: market value
Rules: 5450(b)(2)(C)

Exact text from the filing

April 11, 2023, Impel Pharmaceuticals Inc. (the “Company”) received two written notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The first notification indicated that as of April 11, 2023, the Company did not meet the $15,000,000 minimum market value of publicly held shares required to maintain continued listing as set forth in Nasdaq Marketplace Rule 5450(b)(2)(C) (the “MVPHS Rule”) for the 30-business day period ended April 5, 2023. The second notification indicated that as of April 11, 2023, the Company did not meet the $50,000,000 minimum

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-013092

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.